Skip to main content
padlock icon - secure page this page is secure

Editorial

Buy Article:

$68.00 + tax (Refund Policy)

It is my great pleasure to announce that, since its launch back in 2000, Current Drug Metabolism (henceforth CDM), an interdisciplinary peer-reviewed journal in drug metabolism, has successfully completed eight years of its publication in 2007. Indexed by all major indexing media including Chemical Abstracts, MEDLINE, BIOSIS, Science Citation Index Expanded, etc., this cutting-edge journal is published by Bentham Science Publishers. Bentham Science publishes more than 250 print and open access journals (www.bentham.org), (www.bentham.org/open) and books (www.bentham.org/ebooks).

From 2008 onwards, the journal will publish ten issues. In a relatively short period of time, CDM has achieved an Impact Factor of 5.762 (2006 SCI Journal Citation Reports), one of the very highest in the field. CDM has attained eminence amongst the most leading publications in the field of drug metabolism and represents an important review journal of great value to all academic, government and industrial scientists. . The journal invites contributions for both comprehensive review articles and guest edited issues in all areas of drug metabolism and disposition.

The journal board comprises ten Associate Editors, fifty-six Editorial Board Members and fifty-seven Reviewers. Each Associate Editor of CDM handles peer reviewing of papers received from his/her region on behalf of the Editor-in-Chief. They are also responsible for guest editing and/or soliciting a Hot Topic issue for the journal every year on a contemporary topic falling within the field of drug metabolism.

The journal is also publishing one issue each year dedicated to submissions from the Editorial Board Members of CDM. This is the first such issue and I congratulate to all the contributing Editorial Board Members for their positive response. I strongly believe that the support and contributions from the Editorial Advisory Board have been thoroughly conducive to the success of CDM. I wish to thank each of the Editorial Board Members for their dynamic effort and contribution to this journal and hope they will continue to serve the journal with the same spirit.

I do hope CDM Reader find papers in this issue quite interesting:

Sean Ekins et al. describe molecular characterization of CYP2B6 substrates. They have shown that CYP2B6 substrates are generally small hydrophobic molecules that are frequently central nervous system activated, which may be important for drug discovery research.

Anthony Y. H. Lu et al. in ‘The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters’ hypothesize that the large substrate-binding cavities (SBCs), binding of more than one substrate/effector and binding of substrates in alternative orientations and locations within the SBCs, rotation of a substrate at the active site, and substantial substrate-induced conformational changes of the SBCs are common features of the promiscuous drug metabolizing enzymes, receptors, and transporters, and therefore, are important parameters to be considered in dealing with drug metabolism issues and safety evaluation of drugs and environmental chemicals.

Amin Rostami-Hodjegan et al. have summarized the regulation of synthesis and degradation, methods for determining rates, and implications of cytochrome P450 for the prediction of drug interactions. They reviewed current understanding of CYP regulation, discussed the pros and cons of various in vitro and in vivo approaches used to estimate the turnover of specific CYPs and, by simulation, consider the impact of variability in estimates of CYP turnover on the prediction of enzyme induction and metabolism based inactivation (MBI) in vivo.

Shu-Feng Zhou et al. provided an update on clinical drug interactions with the herbal anti-depressant St. John's wort (SJW). This review highlights and updates the knowledge regarding drug interactions with SJW by a systematic review of all the available evidence, including worldwide published literature and spontaneous case reports......
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: June 1, 2008

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more